China Medical System eyes secondary listing on SGX in July

It aims to expand its Southeast Asia presence and reach Singapore investors.

China Medical System Holdings Limited (CMS), a pharmaceutical company headquartered in Hong Kong, plans to pursue a secondary listing on the Mainboard of the Singapore Exchange (SGX) in July 2025.

Already listed on the Hong Kong Stock Exchange since 2010, CMS has been part of the Hang Seng Large-Mid Cap (Investable) Index and the Hang Seng Innovative Drug Index since 2020 and 2023, respectively.

The secondary listing on SGX aims to deepen CMS’s presence in Southeast Asia and tap into a new investor base in Singapore.

Building on its proven track record attained in China’s pharmaceutical industry, CMS is looking to replicate its success in Southeast Asia.

The group has established Rxilient Health in Singapore as its regional hub, supported by subsidiaries or offices in Malaysia, Vietnam, the Philippines, Indonesia, and Thailand.

To deepen its roots in Southeast Asia, CMS has also acquired a Contract Development and Manufacturing Organisation in Singapore through its associated company, PharmaGend Global.

The 60,290 sqm manufacturing site in Singapore has an annual production capacity of 1 billion oral solid dosage tablets and capsules and started commercial supply production at the end of 2024.